Available Technology
Portfolio of novel monoamine uptake inhibitors targeting monoamine transporters
Technology:
Compounds
Markets Addressed
Monoamine transporters are principal targets of widely used therapeutic agents to treat depression, attention deficit hyperactivity disorder, narcolepsy, obsessive-compulsive disorders, anxiety disorders, nicotine addiction, autism and others. Compounds of this class are also in preclinical evaluation as treatments for Parkinson's disease, neuronal de(re)generation, cognitive enhancement, and fatigue. In addition, compounds targeting monoamine transporters have proven to be effective brain imaging agents to diagnose and monitor disease progression.
Innovations and Advantages
The compounds in this portfolio are mono, double, or triple inhibitors of dopamine, serotonin and norepinephrine reuptake. These uptake inhibitors target the monoamine transporters with various affinities and selectivities. Some have been evaluated in primate models of cocaine addiction and various neuropsychiatric disorders, and further refined to optimize their potential as pharmacotherapeutic agents. In addition, certain compounds have been tested in vivo by brain imaging, to determine their capacity to cross the blood brain barrier and to measure their extent of occupancy of the DA transporter.
Additional Information
Intellectual Property Status: Issued U.S. patent nos.: 7,439,264
Tweet
Inventor(s):
Blundell, Paul
Liu, Shanghao
Madras, Bertha
Meltzer, Peter
Categories:
For further information, please contact:
Michal Preminger, Director of Business Development
(617) 432-0920
Reference Harvard Case #1798